Hepatitis B Virus (HBV)

Atorvastatin calcium: EFFICACY(3)

In all three studies, results at four months showed that the starting dose of atorvastatin 10 mg/day reduced total cholesterol, LDL-C, apo B and triglyceride levels significantly more than did the starting doses of lovastatin (20 mg/day), pravastatin (20 mg/day) or simvastatin (10 mg/day). Improvements in HDL-C were comparable (Table 2). After four months of therapy, more atorvastatin-treated patients were able to meet target LDL-C levels at the starting dose than patients on the starting doses of lovastatin, pravastatin or simvastatin (Table 2). The greater effectiveness of atorvastatin over the other HMG-CoA reductase inhibitors was sustained throughout the one-year treatment period. Take advantage of this opportunity – buy celexa online to enjoy lowest prices online.

TABLE 2 Atorvastatin efficacy in three separate comparative clinical trials with lovastatin, pravastatin and simvastatin (mean percentage change from baseline at four months)

Table2Atorvastatin calcium_A new HMG-CoA reductase inhibitor2

Adapted from references 50-52. *P<0.05 versus statin comparator. Apo B Apolipoprotein B; HDL-C High density lipoprotein cholesterol; LDL-C Low density lipoprotein cholesterol; TG Triglyceride; Total-C Total cholesterol

In the lovastatin comparative trial, overall analysis showed that 27% of patients on atorvastatin and 49% on lo-vastatin had their dose of medication doubled by the end of the study period . In the pravastatin comparative study, by the end of the trial period, 24% of atorvastatin-treated patients had their dose doubled to 20 mg/day compared with 64% of pravastatin-treated patients who had their dose doubled to 40 mg/day . This led to desired LDL-C levels in 71% of atorvastatin-treated patients compared with 26% of patients on pravastatin. In the simvastatin comparative study, 48% of patients on atorvastatin had their dose doubled compared with 62% of simvastatin-treated patients at the end of the study.

Category: Calcium

Tags: Atorvastatin, Coronary artery disease, Dyslipidemia, HMG-CoA reductase inhibitors, Hypercholesterolemia, Statins

Leave a Reply

Your email address will not be published. Required fields are marked *